Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

Patient-focused drug development programme takes first steps

Nature Reviews Drug Discovery volume 12, pages 651–652 (2013)Cite this article

Subjects

First meetings see regulators and patient advocates start working to incorporate the perspective of patients into benefit–risk assessments.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The US Food and Drug Administration's benefit–risk framework.
Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mullard, A. Patient-focused drug development programme takes first steps. Nat Rev Drug Discov 12, 651–652 (2013). https://doi.org/10.1038/nrd4104

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4104

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research